Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Massachusetts General Hospital
40 participants
Aug 31, 2023
INTERVENTIONAL
Conditions
Summary
This is a placebo-controlled, multi-arm phase II platform screening trial designed to test the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies simultaneously in participants with moderate-to-severe pain due to schwannomatosis (SWN). This Master Study is being conducted as a platform that may allow participants with pain associated with schwannomatosis to receive a novel intervention throughout this study. Embedded within the Master Study are individual drug sub-studies: * Investigational Drug Sub-Study A: Siltuximab * Investigation Drug Sub-Study B: Erenumab-Aooe
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A chimeric immunoglobulin G mAb, via intravenous infusion.
Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.
Dextrose 5% in water, via intravenous infusion.
0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05684692